TNFRSF1B and neoplasm: They further provide evidence that, in order to establish optimal personalized, immune-related therapies, in breast cancer patients, one should, in addition to the targeting of the stroma and cancer-infiltrating immune cells (8), also investigate and target tumor cells, as was recently reported for another member of the TNFRSF, TNFR2 (10, 11).